tolerogenic dendritic cells

Phase 2Biologic

UUniversity Hospital, Antwerp

tolerogenic dendritic cells is one of 65 biologic programs targeting Rheumatoid Arthritis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rheumatoid ArthritisActive, not recruiting

Multiple SclerosisActive, not recruiting

Rheumatoid ArthritisPhase 1

Active, not recruiting

Multiple SclerosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Rituxan

Roche

Preclinical

61 2

Orencia

Bristol-Myers Squibb

Preclinical

47 3

Actemra

Enbrel

64 5

Arcoxia

Novartis

Preclinical

4 6

Actos

Takeda

Preclinical

2 7

Zelhou

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

7 8

Kineret

SSwedish Orphan Biovitrum

Preclinical

6 9

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 10

Velcade

SShilpa Grover, MD, MPH

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Not yet recruiting

Multiple Sclerosis

NCT07020715

Clinical

Trials by Indication[1]

Multiple Sclerosis2 trials

A Phase IIa Study of Vitamin D3 Tolerogenic Dendritic Cells (tolDC) for Multiple Sclerosis

Not yet recruiting·UUniversity Hospital, Antwerp·Phase 2·NCT07020715·14 enrolled

A "negative"dendritic Cell-based Vaccine for the Treatment of Multiple Sclerosis: a First-in-human Clinical Trial

Completed·UUniversity Hospital, Antwerp·Phase 1·NCT02618902·9 enrolled

Rheumatoid Arthritis1 trial

Autologous Tolerogenic Dendritic Cells for Treatment of Patients With Rheumatoid Arthritis

Completed·RRussian Academy of Medical Sciences·Phase 1·NCT03337165·10 enrolled

Crohn's Disease1 trial

Intralesional Tolerogenic Dendritic Cells in Crohn's Disease Treatment

Terminated·FFundacion Clinic per a la Recerca Biomédica·Phase 1·NCT02622763·3 enrolled

Safety and Efficacy1 trial

A Clinical Trial Evaluating the Safety and Efficacy of Myelin-peptide Loaded tolDC as Treatment for MS

Withdrawn·UUniversity Hospital, Antwerp·Phase 2·NCT06715605

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for tolerogenic dendritic cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — tolerogenic dendritic cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for tolerogenic dendritic cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Antwerp company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: UUniversity Hospital, Antwerp

tolerogenic dendritic cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Multiple Sclerosis2 trials

Rheumatoid Arthritis1 trial

Crohn's Disease1 trial

Safety and Efficacy1 trial

References

Drug Info

Quick Facts

Related News